… ProQR driving an inclusive culture celebrating Pride Month In … Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians. In June we caught up with our Lead Talent …
… ProQR at TIDES to highlight our Axiomer® technology This month several ProQRians will attend the Oligonucleotide and Peptide … beyond. At this year’s TIDES Europe, Gerard Platenburg, ProQR Chief Scientific Officer, and co-founder, is presenting …
… Today marks an expansion of the ProQR and Lilly partnership In September 2021 ProQR announced a global licensing and research collaboration … originally announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target …
… ProQR Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor conference call and … the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am …
… ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients ProQR presents Positive Top-Line Results from the Phase 1/2 … link . do 10-10-2019 - 08:00 - do 10-10-2019 - 09:00 ProQR presents Positive Top-Line Results from the Phase 1/2 …
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
… ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day LEIDEN, … in non-core therapeutic areas and non-rare diseases. “The ‘ProQR Vision 2023’ strategy presents a clear path for ProQR …
… European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Access … vision with sepofarsen,” stated Daniel A. de Boer, CEO of ProQR. “Looking ahead, our goal is for sepofarsen to reach …
